XQuise
$ALDX 📉📈👀👈🏻
In 4–6 weeks we will surely know more—and not just regarding 2027! 😊
…
FDA discussions are expected in Q4 2026.
A positive decision could potentially revive the development program.
Potential $100 million upfront payment.
Up to approximately $300 million in additional milestones.
Aldeyra requested a transfer of FDA review responsibility to another division.
The previously agreed clinical trial protocol was withdrawn.
Cash: approximately $41 million.
No debt at September 30, 2026.
Expected cash runway into 2029 under the current operating plan.
1
3

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F2a%2F1076.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F08%2F595.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Farticles%2Fmain%2F66%2F1019.jpg)